4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Wuhan YZY Biopharma Co., Ltd. (2496) operates in the Biotechnology industry and is headquartered in Wuhan, China with about 68 employees. Its market capitalization is roughly HK$618 million. In the fiscal year ended 2025-12-31, 2496 reported CNY 67M in revenue and (CNY 85M) in net income.
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-associated complications, and age-related ophthalmologic diseases.
Interactive charts & full statements → Open the 2496 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 67M | CNY 108M | CNY 0M | CNY 0M | — |
| Gross Profit | CNY 11M | CNY 85M | CNY 0M | — | — |
| Operating Income (EBIT) | (CNY 81M) | (CNY 98M) | (CNY 190M) | (CNY 187M) | — |
| Net Income | (CNY 85M) | (CNY 98M) | (CNY 192M) | (CNY 189M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 175M | CNY 268M | CNY 302M | CNY 303M | — |
| Total Liabilities | CNY 228M | CNY 237M | CNY 174M | CNY 147M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2496 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms